Toleranzia AB ( “Toleranzia”) hereby announces that the validation process for the company granted European patent, which protects Toleranzias tolerogenic platform for the treatment of autoimmune diseases, is now complete. The company’s platform technology has thus been granted patent protection to the year 2031 on a substantial part of the European market, involving a population of approximately 400 million.
Toleranzia announced April 28, 2016 the European Patent Office (EPO) approved the company’s patent no. EP2633054, which protects Toleranzias tolerogenic platform for the treatment of autoimmune diseases. For a European patent to apply in individual European countries must, within three months of the EPO’s approval, validated in each country. As a holder of an approved EPO patents have Toleranzia full freedom to select those European countries that are deemed valuable to validate and maintain the patent.
Toleranzia can now announce that the Company, together with its strategic patent agents, HGF Ltd in the UK, conducted a selection and validation process. The eight countries / regions validated the patent, France, Italy, the Netherlands, Switzerland / Liechtenstein, Spain, UK, Germany and Austria.This means that Toleranzias platform technology has a valid patent protection until in 2031 a substantial part of the European market. The patent is already validated and approved in Sweden.
Toleranzias patents are thus approved in nine countries in Europe, and in Australia, China and Japan. The application is the national phase in the US, Canada and India.
Patent protection for the technology platform is generally applicable in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, type 1 diabetes and myasthenia gravis. In addition, the company’s drug candidate in the autoimmune disease myasthenia gravis previously received orphan drug status in Europe and the US, which entails market exclusivity after marketing for ten years in Europe and seven years in the United States.
CEO Charlotte Fribert comments
We have chosen the European countries we consider to be of considerable value to Toleranzia and after the validation process received strong patent protection in Europe. That we already additionally has orphan drug status means that we have both an improved product protection and expanded opportunities for the commercialization of the platform technology as well as myasthenia gravis project on key markets.